Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia

Area of Science:

• Oncology
• Cancer Metabolism
• Molecular Biology

Background:

• Activating mutations in NOTCH1 are prevalent in T cell acute lymphoblastic leukemia (T-ALL).
• Understanding the metabolic dependencies of T-ALL is crucial for developing effective therapies.

Purpose of the Study:

• To identify critical metabolic pathways supporting T-ALL growth downstream of NOTCH1.
• To evaluate glutaminolysis as a therapeutic target in T-ALL, particularly in conjunction with anti-NOTCH1 therapies.

Main Methods:

• Investigated the role of glutaminolysis in T-ALL cell metabolism using in vivo models.
• Assessed the impact of NOTCH1 inhibition on glutaminolysis and autophagy.
• Examined the synergistic effects of combined glutaminolysis and autophagy inhibition with anti-NOTCH1 therapy.
• Analyzed the influence of Pten loss on leukemic cell metabolism and therapy response.

Main Results:

• NOTCH1 signaling directly controls glutaminolysis, a key pathway for T-ALL cell proliferation.
• Inhibition of NOTCH1 leads to metabolic shutdown, decreased glutaminolysis, and activation of autophagy.
• Combined inhibition of glutaminolysis and autophagy synergistically enhances the anti-leukemic effects of anti-NOTCH1 therapy in vivo.
• Pten loss rescues leukemic cell metabolism by upregulating glycolysis, thereby diminishing the efficacy of NOTCH1 inhibition.

Conclusions:

• Glutaminolysis is a critical downstream effector of NOTCH1 signaling in T-ALL.
• Targeting glutaminolysis, in combination with autophagy inhibition, represents a promising therapeutic strategy for T-ALL.
• Understanding metabolic alterations, such as those caused by Pten loss, is essential for optimizing T-ALL treatment strategies.